[
    "als, such as primates (e.g., humans) and rodents (e.g., mice and rats), unless otherwise indicated. In a particular embodiment, the antigen is a human protein. Where reference is made to a particular protein herein, the term encompasses \"full length\" unprocessed protein as well as any form of protein derived from processing in a cell. The term also encompasses naturally occurring variants of the protein, such as splice variants or allelic variants. </p><p id=\"p0164\" num=\"0163\">By \"specific binding\" is meant that the binding is selective for the antigen and can be distinguished from unwanted or non-specific interactions. The ability of an antigen binding molecule to bind a particular antigen can be measured via enzyme-linked immunosorbent assay (ELISA) or other techniques familiar to those skilled in the art, such as Surface Plasmon Resonance (SPR) techniques (analyzed on a BIAcore instrument) (Liljeblad et al, glyco J17, 323-329 (2000)), and conventional binding assays (Heeley, endocr Res 28,217-229 (2002)). In one embodiment, the extent of binding of the antigen binding molecule to an unrelated protein is less than about 10% of binding of the antigen binding molecule to the antigen as measured by, for example, SPR. In certain embodiments, the antigen-binding molecule has a concentration of 1. Mu.M, 100nM, 10nM, 1nM, 0.1nM, 0.01nM, or 0.001nM (e.g., 10 nM) <sup>-8</sup> M or less, e.g. 10 <sup>-8</sup> M to 10 <sup>-13</sup> M, e.g. 10 <sup>-9</sup> M to 10 <sup>-13</sup> M) dissociation constant (Kd).</p><p id=\"p0165\" num=\"0164\">\"affinity\" or \"binding affinity\" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). As used herein, unless otherwise indicated, \"binding affinity\" refers to an intrinsic binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can be generally represented by the dissociation constant (Kd), which is the dissociation and binding rate constants (k, respectively  <sub>off</sub> And k <sub>on</sub> ) Is a ratio of (c). As such, equivalent affinities may comprise different rate constants, provided that the ratio of rate constants remains the same. Affinity can be measured by common methods known in the art, including those described herein. One particular method for measuring affinity is Surface Plasmon Resonance (SPR).</p><p id=\"p0166\" num=\"0165\">The term \"tumor-associated antigen\" means any antigen that is highly expressed by tumor cells or in tumor stroma. The specific tumor associated antigen is CEA or FAP, as well as other targets such as folate receptors.</p><p id=\"p0167\" num=\"0166\">The term \"Fibroblast Activation Protein (FAP)\", also known as prolyl endopeptidase FAP or isolated enzyme (Seprase) (EC 3.4.21), refers to any native FAP from any vertebrate source, including mammals, such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys) and rodents (e.g., mice and rats), unless otherwise indicated. The term includes \"full-length\" unprocessed FAP as well as any form of FAP derived from processing in a cell. The term also encompasses naturally occurring variants of FAP, such as splice variants or allelic variants. In one embodiment, the antigen binding molecules of the invention are capable of specifically binding to human, mouse and/or cynomolgus FAP. The amino acid sequence of human FAP is shown in UniProt (www.uniprot.org) accession n",
    " mammals, such as primates (e.g., humans) and rodents (e.g., mice and rats), unless otherwise indicated. The term encompasses \"full length,\" unprocessed 4-1BB as well as any form of 4-1BB derived from processing in a cell. The term also encompasses naturally occurring variants of 4-1BB, such as splice variants or allelic variants. An exemplary human 4-1BB amino acid sequence is shown in SEQ ID NO:88 (Uniprot accession number Q07011), an exemplary murine 4-1BB amino acid sequence is shown in SEQ ID NO:89 (Uniprot accession number P20334) and an exemplary cynomolgus monkey 4-1BB (from Macaca mulatta) amino acid sequence is shown in SEQ ID NO:90 (Uniprot accession number F6W5G 6).</p><p id=\"p0200\" num=\"0199\">The terms \"anti-4-1 BB antibody\", \"anti-4-1 BB\", \"4-1BB antibody\" and \"antibody that specifically binds 4-1BB\" refer to antibodies that are capable of binding 4-1BB with sufficient affinity such that the antibodies can be used as diagnostic and/or therapeutic agents in targeting 4-1BB. In one embodiment, the anti-4-1 BB antibody binds to an unrelated, non-4-1 BB protein to a lesser extent thanAbout 10% of the binding of the antibody to 4-1BB, as measured, for example, by Radioimmunoassay (RIA) or flow cytometry (FACS). In certain embodiments, an antibody that binds 4-1BB has a concentration of 1. Mu.M, 100nM, 10nM, 1nM, 0.1nM, 0.01nM, or 0.001nM (e.g., 10)  <sup>-6</sup> M or less, e.g. 10 <sup>-68</sup> M to 10 <sup>-13</sup> M, e.g. 10 <sup>-8</sup> M to 10 <sup>-10</sup> Dissociation constant (K) of M) <sub>D</sub> )\u3002</p><p id=\"p0201\" num=\"0200\">The term \"peptide linker\" refers to a peptide comprising one or more amino acids, typically about 2-20 amino acids. Peptide linkers are known in the art or described herein. Suitable non-immunogenic linker peptides are, for example (G) <sub>4</sub> S) <sub>n</sub> ,(SG <sub>4</sub> ) <sub>n</sub> Or G <sub>4</sub> (SG <sub>4</sub> ) <sub>n</sub> Peptide linkers, wherein \"n\" is generally a number between 1 and 10, typically between 2 and 4, in particular 2, i.e. the peptide is selected from the group consisting of GGGGS (SEQ ID NO: 91), GGGGSGGGGS (SEQ ID NO: 92), SGGGGSGGGG (SEQ ID NO: 93), and GGGGSGGGGSGGGG (SEQ ID NO: 94), but also includes the sequence GSPGSSSSGS (SEQ ID NO: 95), (G <sub>4</sub> S) <sub>3</sub> (SEQ ID NO:96),(G <sub>4</sub> S) <sub>4</sub> (SEQ ID NO: 97), GSGSGSGSGS (SEQ ID NO: 98), GSGSGSGNGS (SEQ ID NO: 99), GGSGSGSG (SEQ ID NO: 100), GGSGSG (SEQ ID NO: 101), GGSG (SEQ ID NO: 102), GGSGNGSG (SEQ ID NO: 103), GGNGSGSG (SEQ ID NO: 104) and GGNGSG (SEQ ID NO: 105). Peptide linkers of particular interest are (G <sub>4</sub> S)(SEQ ID NO:91),(G <sub>4</sub> S) <sub>2</sub> And GGGGSGGGGS (SEQ ID NO: 92).</p><p id=\"p0202\" num=\"0201\">The term \"amino acid\" as used in this application refers to a naturally occurring group of carboxy\u03b1 -amino acids, comprising alanine (three letter code: ala, one letter code: A), arginine (arg, R), asparagine (asn, N), aspartic acid (asp, D), cysteine (c",
    " of this new family of proteins are characterized by common structural features and similar intron/exon splice boundaries and exhibit unique expression patterns between hematopoietic cells and non-lymphoid tissues. This gene encodes a B lymphocyte surface molecule that plays a role in B cell development and differentiation into plasma cells. This family member is located at 11q12 between a cluster of family members. Alternative splicing of this gene results in two transcript variants encoding the same protein. The term \"CD20\" encompasses \"full length,\" unprocessed CD20 as well as any form of CD20 derived from processing in a cell. The term also encompasses naturally occurring variants of CD20, such as splice variants or allelic variants. </p><p id=\"p0240\" num=\"0239\">The terms \"anti-CD 20 antibody\" and \"antibody that binds CD 20\" refer to antibodies that are capable of binding CD20 with sufficient affinity such that the antibodies can be used as diagnostic and/or therapeutic agents in targeting CD 20. In one embodiment, the anti-CD 20 antibody pair is absentThe degree of binding of the off, non-CD 20 protein is less than about 10% of the binding of the antibody to CD20, as measured, for example, by Radioimmunoassay (RIA). In certain embodiments, antibodies that bind CD20 have a concentration of 1. Mu.M, 100nM, 10nM, 1nM, 0.1nM, 0.01nM, or 0.001nM (e.g., 10) <sup>-8</sup> M or less, e.g. 10 <sup>-8</sup> M to 10 <sup>-13</sup> M, e.g. 10 <sup>-9</sup> M to 10 <sup>-13</sup> M) dissociation constant (Kd). In certain embodiments, the anti-CD 20 antibody binds to a CD20 epitope that is conserved among CD20 from different species.</p><p id=\"p0241\" num=\"0240\">By \"type II anti-CD 20 antibody\" is meant having a diagnostic et al, blood 103 (2004) 2738-2743; cragg et al, blood 101 (2003) 1045-1052; the binding properties and biological activity of type II anti-CD 20 antibodies described in Klein et al, mAbs 5 (2013), 22-33. Type II anti-CD 20 antibodies bind to a class II epitope on CD20, which does not localize CD20 to lipid rafts, shows ADCC activity, but rather low CDC (if it is an IgG1 isotype antibody), has less ability to bind B cells than antibodies that bind to a class I CD20 epitope, shows homotypic aggregation and strong death induction. Examples of type II anti-CD 20 antibodies include, for example, obbintuzumab You Tuozhu (GA 101), tositumumab (B1), humanized B-Ly1 antibody IgG1 (a chimeric humanized IgG1 antibody as disclosed in WO 2005/044859), 11B8 IgG1 (as disclosed in WO 2004/035607) and AT80 IgG1. In a particular aspect, the type II anti-CD 20 antibody is obbinuteuzumab (recommended INN, WHO pharmaceutical information, vol.26, no.4,2012, p.453). As used herein, obbine You Tuozhu mab is synonymous with GA 101. The trade name is Or (b)This replaces all previous versions (e.g., vol.25, no.1,2011, p.75-76) and was previously referred to as afutuzumab (recommended INN, WHO pharmaceutical information, vol.23, no.2,2009, p.176; vol.22, no.2,2008, p.124). In one aspect,",
    "D-L1\". The amino acid sequence of the complete human PD-L1 is shown in UniProt (www.uniprot.org) accession number Q9NZQ (SEQ ID NO: 110). The term \"PD-L1 binding antagonist\" refers to a molecule that reduces, blocks, inhibits, eliminates or interferes with signal transduction resulting from the interaction of PD-L1 with one or more of its binding partners (such as PD-1, b 7-1). In some embodiments, a PD-L1 binding antagonist is a molecule that inhibits the binding of PD-L1 to its binding partner. In a particular aspect, the PD-L1 binding antagonist inhibits the binding of PD-L1 to PD-1 and/or B7-1. In some embodiments, PD-L1 binding antagonists include anti-PD-L1 antibodies, antigen-binding fragments thereof, immunoadhesins, fusion proteins, oligopeptides, and other molecules that reduce, block, inhibit, eliminate, or interfere with signal transduction resulting from interaction of PD-L1 with one or more of its binding partners (such as PD-1, b 7-1). In one embodiment, the PD-L1 binding antagonist reduces a negative costimulatory signal mediated by or via a cell surface protein expressed on T lymphocytes (via PD-L1 mediated signaling), thereby rendering dysfunctional T cells less dysfunctional (e.g., enhancing effector responses to antigen recognition). In particular, the PD-L1 binding antagonist is an anti-PD-L1 antibody. The term \"anti-PD-L1 antibody\" or \"antibody that binds human PD-L1\" or \"antibody that specifically binds human PD-L1\" or \"antagonistic anti-PD-L1\" means a KD of 1.0x10 <sup>-8</sup> mol/l or less, in one aspect KD of 1.0x10 <sup>-9</sup> Antibodies that specifically bind to human PD-L1 antigen with a binding affinity of mol/L or less. Binding affinity is determined by standard binding assays, such as surface plasmon resonanceGE-Healthcare Uppsala, sweden).</p><p id=\"p0345\" num=\"0344\">In a particular aspect, the agent that blocks PD-L1/PD-1 interaction is an anti-PD-L1 antibody. In one particular aspect, the anti-PD-L1 antibody is selected from the group consisting of atuzumab ((atezolizumab) (MPDL 3280A, RG 7446), durvauumab (MEDI 4736), aviumab (aviumab) (MSB 0010718C) and MDX-1105. In one particular aspect, the anti-PD-L1 antibody is yw243.55.s70 described herein, in another particular aspect, the anti-PD-L1 antibody is MDX-1105. In yet another particular aspect, the anti-PD-L1 antibody is MEDI4736 (cervacizumab), in yet another aspect, the anti-PD-L1 antibody is MSB0010718C (avermectin). More particularly, the agent that blocks PD-L1/PD-1 interactions is atuzumab (L3280A). In another aspect, the agent that blocks PD-L1/PD-1 interaction is an anti-PD-L1 antibody comprising the heavy chain variable domain VH (PDL-1) of SEQ ID NO:114 and the light chain variable domain VL (PDL-1) of SEQ ID NO: 115. </p><p id=\"p0346\" num=\"0345\">The term \"PD-1\", also known as CD279, PD1 or apoptosis protein 1, refers to any natural PD-L1 from any vertebrate source, including mammals, such as primates, e.g. humans and non-human primates (e.g. cynomolgus monkeys), and rodents (e.g. mice and rats), in particular human protein PD-1 having an amino acid sequence as shown in UniProt (www.uniprot.org) accession number Q15116 (SEQ ID NO: 111). The term \"PD-1 binding antagonist\" refers to a molecule that inhibits the binding of PD-1 to its ligand binding partner. In some embodiments, the PD-1 binding antagonist inhibits the binding of PD-1 to PD-L1. In some implementationsIn embodiments, the PD-1 binding antagonist inhibits the binding of PD-1 to PD-L2. In some embodiments, the PD-1 binding antagonist inhibits the binding of PD-1 to both PD-L1 and PD-L2. In particular, the PD-L1 binding antagonist is an anti-PD-L1 antibody. The term \"anti-PD-1 antibody\" or \"antibody that binds to human PD-1\" or \"antibody that specifically binds to human PD-1\" or \"antagonistic anti-PD-1\" refers to a polypeptide having a KD of 1.0x10 <sup>-8</sup> mol/l or less, in one aspect KD of 1.0x10 <sup>-9</sup> An antibody that specifically binds to a human PD1 antigen with a binding affinity of mol/l or less. Binding affinity is determined by standard binding assays, such as surface plasmon resonance GE-Healthcare Uppsala, sweden).</p><p id=\"p0347\" num=\"0346\">In one aspect, the agent that blocks PD-L1/PD-1 interaction is an anti-PD-1 antibody. In a specific aspect, the anti-PD-1 antibody is selected from the group consisting of MDX 1106 (nivolumab), MK-3475 (pembrolizumab), CT-011 (pidizumab), MEDI-0680 (AMP-514), PDR001, REGN2810, and BGB-108, in particular from the group consisting of pembrolizumab and nivolumab. In another aspect, the agent that blocks PD-L1/PD-1 interaction is an anti-PD-1 antibody comprising the heavy chain variable domain VH (PD-1) of SEQ ID NO:116 and the light chain variable domain VL (PD-1) of SEQ ID NO: 117. In another aspect, the agent that blocks PD-L1/PD-1 interaction is an anti-PD-1 antibody comprising the heavy chain variable domain VH (PD-1) of SEQ ID NO:118 and the light chain variable domain VL (PD-1) of SEQ ID NO: 119.</p><p id=\"p0348\" num=\"0347\">Exemplary 4-1BB agonists for use in combination with agents that block PD-L1/PD-1 interactions</p><p id=\"p0349\" num=\"0348\">The invention also relates to a 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to a tumor-associated antigen, for use in a method for treating or delaying progression of cancer, wherein the 4-1BB agonist compris",
    "phate or Tris buffer at a protein concentration of 1mg/ml for up to 17 hours at 37 \u2103. Plasmin or limited LysC (Roche) digestion was performed with 100 \u03bcg of deglycosylated VH/VL CrossMab in Tris buffer pH 8 for 120 hours at room temperature and 40 minutes at 37 \u2103, respectively. Prior to mass spectrometry, samples were desalted via HPLC on a Sephadex G25 column (GE Healthcare). The total mass was determined via ESI-MS on a maXis 4G UHR-QTOF MS system (Bruker Daltonik) equipped with a TriVersa NanoMate source (Advion). </p><p id=\"p1021\" num=\"1019\">Determination of binding and binding affinity of multispecific antibodies to corresponding antigens using Surface Plasmon Resonance (SPR) (BIACORE)</p><p id=\"p1022\" num=\"1020\">Binding of the generated antibodies to the corresponding antigen was investigated by surface plasmon resonance using a BIACORE instrument (GE Healthcare Biosciences AB, uppsala, sweden). Briefly, for affinity measurement, goat anti-human IgG, JIR 109-005-098 antibodies were immobilized on CM5 chips via amine coupling for presentation of antibodies to the corresponding antigens. Binding was measured in HBS buffer (HBS-P (10mM HEPES,150mM NaCl,0.005% tween 20, ph 7.4)) at 25 \u2103 (or alternatively at 37 \u2103). Antigen (R &amp; D Systems or internal purification) was added at various concentrations in solution. Binding was measured by antigen injection for 80 seconds to 3 minutes; dissociation was measured by washing the chip surface with HBS buffer for 3-10 minutes and KD values were estimated using a 1:1 Langmuir (Langmuir) binding model. Negative control data (e.g., buffer curve) is subtracted from the sample curve to correct for intrinsic baseline drift and noise signal reduction in the system. Analysis of the sensorgrams and calculation of the affinity data were performed using the corresponding Biacore evaluation software.</p><p id=\"p1023\" num=\"1021\">Example 1</p><p id=\"p1024\" num=\"1022\">Preparation, purification and characterization of FAP-41BBL antigen binding molecules </p><p id=\"p1025\" num=\"1023\">FAP targeting Fc fusion antigen binding molecules containing a trimer of 4-1BB ligand were prepared as described in International patent application publication No. WO 2016/075278 A1.</p><p id=\"p1026\" num=\"1024\">In particular, the following molecules were generated:</p><p id=\"p1027\" num=\"1025\"><u>a) Monovalent FAP targeting and non-targeting Fc fusion antigen binding molecules containing 4-1BB ligand trimers</u></p><p id=\"p1028\" num=\"1026\">Polypeptides encoding dimeric 4-1BB ligands fused to human CL domains are subcloned in frame with the CH2 and CH3 domains of human IgG1 heavy chains on the festival (Merchant, zhu et al, 1998,Nature Biotechnol.16,677-681). A polypeptide comprising a 4-1BB ligand ectodomain is fused to a human IgG1-CH1 domain. In construct 2.4, to improve correct pairing, the following mutations were additionally introduced in the crossed CH-CL (charged variant). E123R and Q124K in the dimer 4-1BB ligand fused to human CL"
]